Diana Vega
Global Senior Director, Early Detection AstraZeneca
Diana is an innovative and strategic leader committed to improving patient outcomes through her expertise in precision oncology and patient advocacy. She leverages her skills in strategic thinking and partnership building and her deep expertise in cancer research to develop patient-centered solutions in healthcare. Her passion for making personalized care accessible to all patients, regardless of their geographic location, stems from her personal experience with cancer, which drives her efforts to identify and overcome barriers that preclude patients from receiving the best possible care.
For over a decade, Diana has built a reputation for transparency, empathy and resilience, and her work is characterized by an unmatched energy and dedication to the patients that she serves. Diana excels and derives joy from bringing together diverse partners to innovate and implement strategies that prioritize patient needs and long-term health outcomes.
Specialties include genetics, cancer research, biomarker development, diagnostics, liquid biopsy, strategic planning, partnership development, science policy, patient advocacy, education, training, science communication, pediatrics, survivorship, and oncology.
Seminars
- Outlining the evidence regulators expect for ctDNA endpoint consideration, including how multiple myeloma secured its first approval
- Identifying gaps between exploratory biomarker use and surrogate endpoint qualification
- Positioning ctDNA endpoints for inclusion in regulatory dialogue and submission packages
- Reframing early detection as a strategic extension of drug development, not a departure from it
- Using ctDNA and emerging assays to guide earlier intervention, adjuvant decisions, and monitoring
- Aligning innovation with the ambition to eliminate cancer as a cause of death
